Eric Nadler, MD

Subcutaneous cancer therapy cuts chair time and IV needs, but brings site reactions, volume limits, and policy hurdles clinics must solve.

Subcutaneous cancer therapy trims chair time and costs, but volume limits and reactions matter—learn how clinics streamline workflows.

Experts decode NSCLC PD‑L1 trials, when immunotherapy alone works, why crossover matters, and who still benefits from adding chemotherapy.

Clinicians weigh dual immunotherapy vs monotherapy in metastatic NSCLC, comparing CheckMate 227 and POSEIDON efficacy, PD‑L1 subsets, and toxicity.

Experts explain stage IV lung cancer goals, PD‑L1-driven therapy choices, and when to intensify with chemo plus dual immunotherapy.

Experts explain stage IV lung cancer goals, PD‑L1-driven therapy choices, and when to intensify with chemo plus dual immunotherapy.

Experts weigh neoadjuvant vs adjuvant immunotherapy in resectable lung cancer, balancing PD‑L1, pCR, surgery timing, and toxicity.

Experts weigh lung cancer perioperative immunotherapy trials, debating adjuvant nivolumab, ctDNA guidance, and chemo choices versus pembrolizumab data.

How EGFR, ALK and PD-L1 biomarker results shape neoadjuvant lung cancer therapy—and what CheckMate-816 means for survival.

Experts discuss the evolving role of PD-L1 in guiding perioperative treatment decisions for resectable NSCLC and review the pivotal CheckMate 816 trial, which established neoadjuvant nivolumab plus chemotherapy as a standard-of-care option based on improved pathologic response and event-free survival outcomes.

Experts discuss how treatment strategies for NSCLC differ between resectable and metastatic disease, emphasizing a multimodal, curative approach in early-stage cancer versus personalized systemic therapy focused on disease control and survival in advanced stages.